S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Legendary Stockpicker: "Buy this A.I. stock NOW" (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Biden To Unleash "Choke Point" Operation On America? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Biden To Unleash "Choke Point" Operation On America? (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Legendary Stockpicker: "Buy this A.I. stock NOW" (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Biden To Unleash "Choke Point" Operation On America? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Biden To Unleash "Choke Point" Operation On America? (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Legendary Stockpicker: "Buy this A.I. stock NOW" (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Biden To Unleash "Choke Point" Operation On America? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Biden To Unleash "Choke Point" Operation On America? (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Legendary Stockpicker: "Buy this A.I. stock NOW" (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Biden To Unleash "Choke Point" Operation On America? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Biden To Unleash "Choke Point" Operation On America? (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:MDGL

Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price & News

$153.34
-6.17 (-3.87%)
(As of 09/22/2023 ET)
Compare
Today's Range
$151.42
$161.72
50-Day Range
$153.34
$223.03
52-Week Range
$57.21
$322.67
Volume
393,502 shs
Average Volume
368,866 shs
Market Capitalization
$2.83 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$309.18

Madrigal Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
101.6% Upside
$309.18 Price Target
Short Interest
Bearish
15.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.92
Upright™ Environmental Score
News Sentiment
0.30mentions of Madrigal Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($18.77) to ($8.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

149th out of 963 stocks

Pharmaceutical Preparations Industry

49th out of 457 stocks


MDGL stock logo

About Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.

MDGL Price History

MDGL Stock News Headlines

His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
The Latest Analyst Ratings for Madrigal Pharmaceuticals
John Paulson's Q2 2023 13F Filing Update
See More Headlines
Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Company Calendar

Last Earnings
8/08/2023
Today
9/24/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MDGL
CUSIP
87162T20
Employees
92
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$309.18
High Stock Price Forecast
$390.00
Low Stock Price Forecast
$224.00
Forecasted Upside/Downside
+101.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Net Income
$-295,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$11.54 per share

Miscellaneous

Free Float
14,053,000
Market Cap
$2.83 billion
Optionable
Optionable
Beta
-0.72

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Rebecca A. Taub M.D. (Age 71)
    Founder, Chief Medical Officer, Pres of R&D and Director
    Comp: $939.83k
  • Mr. Alex G. Howarth (Age 54)
    Sr. VP & CFO
    Comp: $757.26k
  • Mr. Brian J. Lynch J.D. (Age 61)
    Sr. VP & Gen. Counsel
    Comp: $763.75k
  • Mr. Remy Sukhija (Age 51)
    Sr. VP & Chief Commercial Officer
    Comp: $785.2k
  • Mr. William J. Sibold (Age 57)
    CEO & Director
  • Dr. Kianoush Motesharei Ph.d. (Age 53)
    Sr. VP of Bus. & Corp. Devel.
  • Mr. Edward Chiang
    Sr. VP of Clinical & Technical Operations
  • Mr. Thomas W. Hare
    Sr. VP of Clinical Management
  • Dr. Robert E. Waltermire Ph.D. (Age 59)
    Chief Pharmaceutical Devel. Officer
  • Dr. Stephen Dodge M.B.A.
    Pharm.D., Sr. VP of Global Medical Affairs













MDGL Stock - Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MDGL shares.
View MDGL analyst ratings
or view top-rated stocks.

What is Madrigal Pharmaceuticals' stock price forecast for 2023?

11 analysts have issued twelve-month price objectives for Madrigal Pharmaceuticals' shares. Their MDGL share price forecasts range from $224.00 to $390.00. On average, they predict the company's share price to reach $309.18 in the next year. This suggests a possible upside of 101.6% from the stock's current price.
View analysts price targets for MDGL
or view top-rated stocks among Wall Street analysts.

How have MDGL shares performed in 2023?

Madrigal Pharmaceuticals' stock was trading at $290.25 on January 1st, 2023. Since then, MDGL shares have decreased by 47.2% and is now trading at $153.34.
View the best growth stocks for 2023 here
.

When is Madrigal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our MDGL earnings forecast
.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($4.69) EPS for the quarter, missing analysts' consensus estimates of ($4.59) by $0.10.

What ETFs hold Madrigal Pharmaceuticals' stock?
What other stocks do shareholders of Madrigal Pharmaceuticals own?
What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.65%), State Street Corp (2.94%), Assenagon Asset Management S.A. (2.55%), Marshall Wace LLP (2.49%), Alliancebernstein L.P. (2.01%) and Perceptive Advisors LLC (1.64%). Insiders that own company stock include Brian Joseph Lynch, Remy Sukhija and Richard S Levy.
View institutional ownership trends
.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $153.34.

How much money does Madrigal Pharmaceuticals make?

Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $2.83 billion. The biopharmaceutical company earns $-295,350,000.00 in net income (profit) each year or ($18.65) on an earnings per share basis.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for the company is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (267) 824-2827, via email at ir@madrigalpharma.com, or via fax at 781-274-8228.

This page (NASDAQ:MDGL) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -